United States Patent 8,349,843: scope, claim construction drivers, and US patent landscape for a formula-I pharmaceutical composition
United States Patent 8,349,843 claims a broad “formula I” pharmaceutical composition defined by: (i) a large, substituted heteroaryl/aryl scaffold with variable substituents R, R2, X, R3, R4-R5, R6, and (ii) explicitly defined hetero-atom constraints (Y and Z are oxygen) plus (iii) use in a pharmaceutically acceptable carrier. The claim set you provided is expansive on chemical space (multiple C1-C8 and aryl substitution options, ring-forming substitutions, and oxo/hetero-functional allowances), which typically supports broad coverage but also raises common validity and non-infringement interpretation points in litigation: whether the accused compound falls within the enumerated substituent classes and whether it matches the specified linkage/ring-formation logic for X and R3 relative to CR14.
What does US patent 8,349,843 claim in “formula I” terms?
Answer (practical claim scope): The claim covers a pharmaceutical composition containing a compound of formula I (or salt) where specific variables are constrained to enumerated substituent classes, including:
- R: COOH or prodrug-like group hydrolyzable to COOH
- R2: C1-C4-alkyl or C1-C4-alkoxy
- X: defined by CR14, with ring-forming substitution option (CR14 forming a 5- or 6-membered alkylene/alkenylene ring with CR3) and with a methylene to oxygen replacement allowance
- R3: C1-C4-alkyl or C1-C4-alkoxy, or linked to CR14 to yield the 5- or 6-membered ring
- R4/R5: multiple aromatic and hetero substitutions including phenyl/naphthyl, tether units (methylene/ethylene/ethenylene), and hetero atoms (O, S, SO2, NH, N-alkyl)
- R6: hydrogen, C1-C8 alkyl, or C3-C8 cycloalkyl, with multiple substituent classes on that radical, or alternatively R6 is phenyl/naphthyl with its own substituent set
- Y and Z: both are oxygen
- carrier: pharmaceutically acceptable carrier
Claim type: composition claim (not a method-of-use claim in the text you provided). That matters because composition claims can read on marketed formulations if the active ingredient is within formula I.
How do the substituent variables (R, R2, X, R3, R4-R5, R6) drive infringement coverage?
R: COOH or hydrolyzable to COOH
- Literal scope: requires a carboxylic acid group or a group hydrolyzable to COOH.
- Infringement driver: most “inactive ester” prodrugs (e.g., ester prodrugs) can still satisfy the “hydrolyzable to COOH” language if the chemistry and in vivo/in vitro hydrolysis support the hydrolyzability characterization.
R2: C1-C4-alkyl or C1-C4-alkoxy
- Narrows to relatively small groups (methyl/ethyl/propyl/butyl and methoxy/ethoxy/propoxy/butoxy).
X and R3: CR14 plus ring-forming logic
This is the most structurally technical part of your claim language.
X definition:
- X is CR14
- R14 is hydrogen or C1-C5-alkyl
- Additionally, CR14 can form together with CR3 a 5- or 6-membered alkylene or alkenylene ring
- That ring can be substituted by one or two C1-C4-alkyl groups
- In each case, a methylene group can be replaced by an oxygen
R3 definition:
- R3 is C1-C4-alkyl or C1-C4-alkoxy, OR
- R3 is linked to CR14 “as indicated above” to give the ring
Infringement driver: an accused structure must satisfy either:
- the “X is CR14, R14 is H or C1-C5-alkyl” condition without the ring linkage, or
- the explicit “ring formed between CR14 and CR3” construction, including ring size (5 or 6), ring type (alkylene/alkenylene), allowed substitution count (one or two C1-C4-alkyl), and oxygen replacement allowance (methylene to O in “each case”).
Litigation driver: courts often focus on claim construction of such “linkage logic” terms. If an accused compound uses a different heteroatom replacement pattern, ring size, or linkage geometry, it can fall outside literal scope even if it seems chemically close.
R4 and R5: broad aromatic/tether/heteroatom set
R4 and R5 are each independently:
- phenyl or naphthyl
- methylene, ethylene, or ethenylene group
- oxygen or sulfur
- SO2
- NH or N-alkyl
- C3-C7 cycloalkyl
This is a high-permissiveness scaffold element and can enable coverage across many analogs.
R6: two alternative regimes
Your claim gives two alternative definitions for R6:
Regime A:
- R6 is hydrogen, C1-C8 alkyl, or C3-C8 cycloalkyl
- and each of these radicals can be substituted with a substituent list (halogen, nitro, cyano, C1-C4 alkoxy, alkenyloxy/alkynyloxy, thioethers, haloalkoxy, carbonyl-containing groups, alkylamino and diarylamino-like patterns, and phenyl/phenoxy substituted phenyl/phenoxy variants with their own substituent sets).
Regime B:
- R6 is phenyl or naphthyl, each substituted with radicals from a defined list including halogen, nitro, cyano, hydroxyl, amino, C1-C4 alkyl, haloalkyl, alkoxy, haloalkoxy, phenoxy, C1-C4 alkylthio, and alkylamino/dialkylamino/dioxomethylene/dioxoethylene.
Infringement driver: This design makes it harder for competitors to avoid infringement by tweaking peripheral groups on R6. Avoidance requires moving out of one of the explicit constraints, like changing Y/Z away from oxygen or breaking the R/X/R3 ring constraints.
What do Y and Z being oxygen mean for freedom-to-operate?
Your claim requires:
Impact:
- This is an anchoring constraint. Many near-neighbor analogs vary ring heteroatoms (e.g., replacing an O with S or N) to change potency or PK. If the accused structure has non-oxygen at either position, it typically exits literal coverage.
How broad is the claim, in practical search space terms?
Even without the missing “formula I” drawing, the variable definitions you provided indicate a broad Markush-style framework:
- Multiple aliphatic options across R2, R14, and R3
- Optional ring formation between CR14 and CR3 with oxygen replacement
- R4/R5 independent choice from aromatic/tether/hetero options including SO2
- Peripheral substitution on R6 from a wide enumerated set including halo, nitro, cyano, various oxy and thio patterns, and multiple carbonyls and amines
Business interpretation: This kind of claim often targets a drug series (many analogs share the core “formula I” but vary substituents). It tends to produce:
- stronger enforcement when competitors stay within the series,
- weaker reach against series with different heteroatom substitution at Y or Z,
- increased litigation focus on ring linkage and exact allowed oxygen replacement patterns.
What patentability risks and claim-construction issues commonly apply to this claim structure?
1) Definiteness and Markush breadth
Broad enumerations can trigger disputes over whether the claim reasonably defines the invention with sufficient precision. Your provided text appears to use standard “can be substituted by” and class definitions, which usually survive if the underlying application provides adequate support.
2) Enablement and written description
If formula I covers many substituent combinations, challengers often attack whether the specification enables all embodiments across the full range, especially where ring oxygen replacement and various carbonyl/amine substituents are allowed. These attacks are case-specific but are common where the variable ranges are large.
3) Literal infringement vs equivalents
The explicit constraints (Y/Z oxygen, R hydrolyzable to COOH, X/R3 ring-formation conditions) tend to constrain the “literal” reach. Courts may treat those as meaningful limitations, narrowing equivalents.
4) Ring formation limitation is a likely dispute hotspot
The “CR14 forms together with CR3 a 5- or 6-membered alkylene or alkenylene ring” plus “one or two C1-C4-alkyl substitutions” and “methylene replaced by oxygen” language is a classic basis for non-infringement if the accused compound:
- uses 4- or 7-membered rings,
- uses different heteroatom placement rules,
- forms the ring via a different linkage position than the claim implies.
What other US patents typically surround a composition claim like 8,349,843?
Without the prosecution history, family data, and the Orange Book listing for the relevant drug product, a complete US “landscape map” cannot be built from the claim text alone. Under normal pharma patent practice, a composition claim like this typically coexists with one or more of the following US patent classes:
A) Compound (API) patents
- Similar formula I scaffold claims covering active ingredient embodiments, including salts.
B) Prodrug / ester patents
- Especially where R includes “can be hydrolyzed to COOH,” families often include specific prodrug esters and their stereochemistry.
C) Formulation patents
- Tablets/capsules, controlled release matrices, solubility-enhancing formulations.
- Composition claims like yours may still be paired with formulation patents because “composition” at API level does not protect manufacturing excipients and release profiles.
D) Method-of-use patents
- Dosing regimens and indications.
E) Polymorph/crystal form patents
- Common where the API has solid-state variants.
Key point: for freedom-to-operate, the “adjacent” patents matter as much as the composition claim. Even if 8,349,843 is narrow on a particular heteroatom or ring linkage, other family members may cover different embodiments that overlap commercial candidates.
What does the claim imply about generic entry risk (ANDA) and biosimilar risk?
ANDA / small-molecule generic risk
If 8,349,843 is tied to a marketed small-molecule active ingredient that matches formula I, the primary ANDA risk is:
- Paragraph IV exposure against API-level claims if the generic’s ANDA active ingredient falls inside the claim’s Markush limits (R, R2, X/R3 ring logic, R4/R5, R6 substitution, and Y/Z oxygen constraints).
- Even if the generic changes substituents, it may still fall within the enumerated classes, especially around R4/R5 and R6.
Biosimilar risk
This claim is for a chemical composition with explicit substituent variables and oxygen constraints, not for biologics. Biosimilar litigation is not the relevant pathway for this specific claim.
Key takeaways
- 8,349,843 is a broad Markush composition claim built around a formula I scaffold with numerous permissible substituent classes.
- The strongest structural “hard stops” are Y and Z being oxygen and the X/R3 ring-formation/linkage logic tied to CR14 and CR3.
- Peripheral substitution at R6 is extremely permissive, making avoidance by minor substitution changes unlikely if the core scaffold constraints are met.
- The risk in litigation typically centers on exact scaffold mapping, especially how the accused compound satisfies (or does not satisfy) the ring-formation conditions involving CR14/CR3 and the methylene-to-oxygen replacement concept.
- A complete US landscape requires more than claim text (Orange Book status, family members, and prosecution history), which is not supplied here; the claim alone supports a conclusion about scope mechanics, not a defensible portfolio map.
FAQs
1) What are the primary non-infringement levers in US 8,349,843?
Breaking explicit limitations tied to Y/Z oxygen or failing the X-CR14 and R3 ring-forming linkage requirements (ring size/type and oxygen replacement constraints) are the most direct levers.
2) Does the claim cover ester prodrugs if R can hydrolyze to COOH?
Yes. The claim includes R groups that can be hydrolyzed to COOH, which commonly captures ester and related prodrug motifs if they meet the hydrolyzability definition used in the claim and supported in the specification.
3) Are small changes to substituents on R6 a meaningful design-around?
Often not. R6 substitution is defined broadly with large enumerated sets including halogens, alkoxy/thio, carbonyl and amino patterns, and phenyl/phenoxy substitution. Design-around typically requires exiting a harder constraint like Y/Z oxygen or X/R3 linkage logic.
4) Is the claim limited to a particular dosage form or route of administration?
From the provided claim language, it is not limited to a dosage form or route. It requires only a pharmaceutical composition with a pharmaceutically acceptable carrier.
5) Is biosimilar entry relevant to this patent?
No. The claim is for a small-molecule-type chemical composition defined by explicit structural variables, not a biologic.
References (APA)
- United States Patent 8,349,843. (n.d.). United States Patent and Trademark Office.
